News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News ASCO to shine light on CAR-T developments Kite, Juno, and BlueBird will give updates on T-cell therapies.
Views & Analysis ASCO 2017: Breast cancer next target for Keytruda Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.
Views & Analysis Tunnah’s musings: Lessons for pharma from digital ASCO 2016 Pharma needs to remedy its approach to digital conference engagement.
Views & Analysis A European perspective on oncology: ASCO review An overview of the latest on immunotherapies, progress in multiple myeloma and benefits of patient-reported outcomes.
Views & Analysis Digital healthcare round-up: ASCO apps, public health, weara... A round-up of this week's top digital healthcare news. Marco Ricci reports.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
